Jim Erickson, UltiMed, Inc. CEO, featured on The Honest Apothecary

  • March 17, 2020

Our CEO, Jim Erickson, was recently interviewed by The Honest Apothecary about UltiMed and the UltiGuard Safe Pack.

To read the full article, click here.

UltiGuard® Safe Pack Insulin Syringes make the grade as a preferred product at Fear Free

  • January 14, 2020
  • Corporate News

[Excelsior, Minnesota] UltiMed, Inc. announces that its patented UltiGuard Safe Pack has been added to the Fear Free, LLC Preferred Product Program. UltiGuard Safe Pack is the only insulin syringe that combines premium-quality, human-grade syringes with a sharps container.

We recently talked with Kristin Hook, DVM, medical director and CEO of Furever Family Veterinary Care Clinic in East Moline, Ill. Dr. Hook’s clinic and 100% of her staff are Fear Free Certified, which means they work to take fear out of veterinary visits for pets and their owners. “UltiGuard Safe Pack syringes fit the bill,” says Dr. Hook. “It’s already scary for owners to treat their pets’ diabetes, so let’s make the experience as worry-free as possible.”

UltiGuard Safe Pack not only provides human-grade, ultra-fine insulin syringes—the all-in-one system removes the concern about what to do with the syringes after treatment.

Surveys indicate that less than 5% of the more than 7.8 billion sharps sold in the United States annually are disposed of in a closed container. The other 95% are deposited, unprotected, into household trash, putting individuals at risk for accidental needle sticks.

Dr. Hook says her clinic occasionally receives plastic baggies, cardboard boxes and plastic milk cartons with used syringes. “I’ve even heard of people just throwing them in the trash,” she says, “and that’s a public health concern that makes me nervous.” Proper disposal of sharps is recommended and required by government agencies.

Requirements for proper disposal vary, but in every state you must:

  • Place sharps in commercially available sharps containers or puncture resistant plastic or metal containers with a tightly secured screw-on lid. Do not use a clear or glass containers.
  • Label containers with: SHARPS. DO NOT RECYCLE.
  • Seal containers with heavy-duty tape.

Additional options may include a mail-back program (fees apply), medical waste collection program or a sharps needle destruction device to destroy used needles and lancets.

Find your state’s specific requirements at https://www.ulticare.com/state-disposal-guidelines.

This game-changing treatment and disposal system not only provides a comfortable injection experience for the pet, it also removes the concern of how to discard sharps.

Visit UltiMed booth #1509 at VMX 2020 in Orlando, Fla., January 18-22 to learn more about this ground-breaking product.

About UltiMed, Inc.
UltiMed, Inc., headquartered in Excelsior, Minnesota, is a manufacturer of drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and other specialty syringes with focus on serving people and pets with diabetes. The company owns and operates two state-of-the-art medical device manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world.

About Fear Free

“Our mission is to prevent and alleviate fear, anxiety, and stress in pets by inspiring and educating the people who care for them.”

Developed by America’s Veterinarian, Dr. Marty Becker, Fear Free offers online and in-person education to veterinary professionals, pet professionals, and pet owners. Fear Free provides both professionals and pet lovers alike with the knowledge and tools to look after a pet’s physical and emotional well-being.

###

If you’d like more information about this topic, or to schedule an interview, please call Tim Rosen, Sr. Marketing Manager, at (651) 291-7909 ext. 209 or e-mail at T.Rosen@ultimedinc.com.

UltiMed Corporate Office Moves to Excelsior, Minnesota

  • September 27, 2014
  • Corporate News

Excelsior, MN – UltiMed Inc., a rapidly growing manufacturer and distributor of pen needles, insulin syringes and other injection related products to the consumer, institutional and veterinary markets has relocated its corporate office to Excelsior, Minnesota.

“We‘re very excited to be part of a great community,” said Holly Hartshorn, UltiMed Director of Marketing. “The new location accommodates our need for more space as we grow and provides a variety of entertainment and dining choices for our team and customers. We look forward to learning more about the area and exploring all it has to offer.”

About UltiMed Inc.
UltiMed, Inc., headquartered in Excelsior, MN, is a manufacturer of drug injection delivery devices including insulin syringes, pen needles and safety syringes for the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed’s broad product offering is valued by pharmacies, physician offices, health care facilities and veterinary clinics. UltiMed’s exclusive UltiGuard® packaging system makes the Company a world leader in safe needle disposal. The UltiGuard® package combines convenient needle storage and a sharps disposal container all in one system, ensuring used needles are properly contained after use. For more information, visit www.ulticare.com.

If you’d like more information about this topic, or to schedule an interview with Holly Hartshorn, please call Holly at (651) 291-7909, X211 or e-mail at h.hartshorn@ulticare.com

UltiMed Inc. Partners with Growth Oriented Investor

  • September 25, 2014
  • Corporate News

Excelsior, MN – UltiMed Inc., a rapidly growing manufacturer and distributor of pen needles, insulin syringes and other injection related products to the consumer, institutional and veterinary markets, today announced that it has been acquired by LDI Ltd. Based in Indianapolis, LDI is a family office that invests in growth oriented businesses. UltiMed is headquartered in Minneapolis and owns and operates manufacturing facilities in De Smet, SD and South Korea.

For over 25 years, UltiMed has provided diabetes patients with smooth and comfortable injection devices. UltiMed products are complemented by a proprietary dispense and dispose packaging system that enables patients to more easily and safely dispose of used sharps. The company markets its products under the UltiCare® brand, as well as under private label and co-branding arrangements.

“Our manufacturing business is a great fit with LDI,” said Jim Erickson, UltiMed President. “Our new relationship with LDI will give us greater resources to provide enhanced products and services. This will help our business partners and healthcare professionals better treat and manage the needs of their customers and patients. We welcome LDI’s experience in building businesses and their culture as a family office. We are excited to partner together to grow our business.”

This acquisition signifies an exciting opportunity for LDI, led by President and CEO J.A. Lacy.

“Jim Erickson and the UltiMed management team have built a growing and profitable company based on high-quality, user-friendly products and a commitment to customer service,” said Lacy. “We are excited to work with the UltiMed team on a strategy to accelerate their growth and welcome them to the LDI family.”

About UltiMed Inc.
UltiMed, Inc., headquartered in Excelsior, MN, is a manufacturer of drug injection delivery devices including insulin syringes, pen needles and safety syringes for the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed’s broad product offering is valued by pharmacies, physician offices, health care facilities and veterinary clinics. UltiMed’s exclusive UltiGuard® packaging system makes the Company a world leader in safe needle disposal. The UltiGuard® package combines convenient needle storage and a sharps disposal container all in one system, ensuring used needles are properly contained after use. For more information, visit www.ulticare.com.

About LDI Ltd.
LDI is an Indianapolis-based family office with more than a century of experience operating high-potential, middle-market companies. Originally founded by the Lacy family in 1912 as U.S. Corrugated-Fibre Box Company, LDI today seeks investments in manufacturing, distribution and logistics businesses. LDI businesses employ more than 2,500 people in more than 20 countries. LDI employs an investment strategy to build enduring value through customer focus and continued improvement over long term investment horizons.

If you’d like more information about this topic, or to schedule an interview with Holly Hartshorn, please call Holly at (651) 291-7909, X211 or e-mail at h.hartshorn@ulticare.com

UltiMed improves patient comfort with new UltiCare® Micro 4mm x 32G pen needle

  • March 20, 2012
  • Corporate News

St. Paul, MN – March 19, 2012 – UltiMed announces the launch of the new 4mm x 32G UltiCare® Micro pen needle, their shortest, thinnest pen needle providing a more comfortable injection for patients living with diabetes.

The UltiCare® Micro offers all the comfort features of the leading pen needle at a lower cost to pharmacists and a less painful injection experience to the patient.

UltiMed is one of only a few pen needle manufacturers, and follows all ISO standards for pen needles, providing added quality assurance testing other pen needle distributors cannot.

The new Micro 4mm x 32G pen needle is compatible with all pens sold in the U.S. and is available in a easy to dispense 50-count box or 100-count UltiGuard® Safe Pack that combines pen needles and an approved sharps container all in one system.

About UltiMed, Inc.
UltiMed, Inc., headquartered in St. Paul, Minnesota is a manufacturer diabetic drug delivery devices and specialty safety syringe devices, including insulin syringes, pen needles and other specialty syringes for domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world.

If you’d like more information about this topic, or to schedule an interview with Holly Hartshorn, please call Holly at (651) 291-7909, X211 or e-mail at h.hartshorn@ulticare.com

UltiMed, Inc. begins manufacturing pen needles in the U.S.

  • November 12, 2011
  • Corporate News

St. Paul, MN – November 11, 2011 – UltiMed, Inc. announced the beginning of the manufacture of pen needles at its DeSmet, South Dakota facilities.

Pen needles are used on pen injectors. Pen injectors are designed for more convenient injection of insulin and other self injected medications. Pen injection is the most popular means of administrating medications in many of the world’s developed areas including Europe, Canada and Asia. Pen injection is increasing being used by self injectors in the United States.

UltiMed designed its manufacturing facility in DeSmet in anticipation of a large and rapid growth in pen needle demand. Therefore future capacity additions to UltiMed’s DeSmet pen needle production can be done rapidly and efficiently.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. announces the promotion of Brahim Zabeli to Sr. Vice President

  • March 10, 2011
  • Corporate News

St. Paul, MN – March 9, 2011 – UltiMed, Inc. announced today the promotion of Brahim Zabeli to Sr. Vice President of Sales and Marketing.

Mr. Zabeli has served as the Vice President of U.S. Diabetes Care division since September 2010. In his new capacity, Zabeli will oversee all marketing and sales management programs.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. Announces New Product Launch of 50-Count Pen Needle

  • March 04, 2011
  • Corporate News

St. Paul, MN – March 3, 2011 – UltiMed, Inc. announces the launch of a new 50-count pen needle.

Traditionally pen needles have been dispensed in quantities of 100; however, one of the world’s largest retailers currently offers a 50-count pen needle under their private-label brand. The launch of UltiMed’s new 50-count pen needle opens up distribution for a high quality cost effective pen needle to all retail and independent pharmacies. Over the past decade many diabetes patients have seen their co-pays rise to a point where it may actually be less expensive to simply buy their pen needles with cash. UltiMed’s products are covered by most insurance plans, so for those that have good insurance coverage they can continue to pay their co-pay.

The new easy-dispense box was designed with the consumer and pharmacist in mind. The unique design makes it easy for patients to dispense their pen needles. It also allows pharmacists several ways to display the product and whichever option they choose, the essential information needed to fill a patient’s prescription is always highly visible.

UltiMed, Inc. manufactures their premium quality universal-fit pen needles in their De Smet, South Dakota factory and offers the only U.S. assembled pen needle. Their products allow pharmacists to offer diabetes patients all the comfort of the leading brand while increasing their profit margins.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery devices, including insulin syringes and pen needles for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world.

UltiMed, Inc. introduces new Insulin Safety Syringe line

  • February 10, 2011
  • Corporate News

St. Paul, MN – February 19, 2011 – UltiMed, Inc. announced today the introduction of the new UltiCare® Insulin Safety Syringe line.

The UltiCare safety-engineered insulin syringes are a premium quality, low-cost alternative that protect both the patient and healthcare provider. The low dead space design technology reduces medication waste and cost by precisely and accurately delivering each dose. The introduction of the UltiCare Insulin Safety Syringe fills a void in a competitive market and offers customers an alternative safety insulin syringe. UltiMed, Inc. continues to be an innovative leader in specialty low dead space syringe development.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. announces expansion of U.S. pen needle manufacturing

  • December 15, 2010
  • Corporate News

St. Paul, MN – December 14, 2010 – UltiMed, Inc. announced the completion of the installation of its new, fully automated pen needle packaging machine.

Without full automation, the counting and packaging of UltiMed’s dual use packaging style was labor intensive. With the addition of the new fully automated packaging machinery, the counting and packaging of pen needles, including case sealing, can be done at a rapid rate with just one operator.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. introduces new Tuberculin Safety Syringe line

  • November 04, 2010
  • Corporate News

St. Paul, MN – November 3, 2010 – UltiMed, Inc. announced today the introduction of the new UltiCare® Tuberculin Safety Syringe line.

The UltiCare safety-engineered tuberculin syringes are a premium quality, low-cost alternative that protect both the patient and healthcare provider. The low dead space design technology reduces medication waste and cost by precisely and accurately delivering each dose. The introduction of the UltiCare Tuberculin Safety Syringe fills a void in a competitive market and offers customers an alternative safety tuberculin syringe. UltiMed, Inc. continues to be an innovative leader in specialty low dead space syringe development.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. announces addition of Brahim Zabeli as Vice President of US Diabetes

  • September 25, 2010
  • Corporate News

St. Paul, MN – September 24, 2010 – Brahim Zabeli joins UltiMed, Inc. as Vice President of U.S. Diabetes Care.

UltiMed, Inc. announced today that Brahim Zabeli has joined the team as Vice President of U.S. Diabetes Care. Mr. Zabeli comes to UltiMed, Inc. from the world market leader in syringes and pen needles, Becton Dickinson (BD) (ticker: BDX). At BD, Mr. Zabeli was the Director of U.S. Retail Sales & Managed Markets. He was also a member of the BD Diabetes Care Global Extended Leadership Team. In the U.S. market, Mr. Zabeli’s team developed and implemented plans which grew the core insulin delivery business to 83% market share. Mr. Zabeli was directly involved in the successful contract negotiations with key strategic customers, including: Caremark, CVS, Walgreen’s, Walmart and Target. Prior to BD, Mr. Zabeli held positions of VP Sales & Marketing, Area Manager, National Account Manager, Account Representative and Division Manager at Arkray USA (fka (Hypoguard), LifeScan (a Johnson & Johnson Company), and Pfizer Consumer Health (fkaWhitehall-Robins Healthcare/ Wyeth Consumer Healthcare. Mr. Zabeli has a BA from State University of New York at Buffalo and an MBA from The Claremont Graduate University.

In his new capacity, Zabeli will oversee all marketing and sales management programs for U.S. Diabetes Care division.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. develops products for International markets

  • October 06, 2009
  • Corporate News

St. Paul, MN – October 5, 2009 – UltiMed, Inc. announces the introduction of a yellow UltiGuard™ package style for distribution in international markets at the Canadian Diabetes Association Professional Conference in Montreal. The unique and exclusive UltiGuard package style combines premium quality needles and an approved sharps container all in one system. The introduction of a yellow UltiGuard meets the sharps compliance standards for Canada and Europe.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.